Eli Lilly's oral GLP-1 Foundayo shows efficacy in sleep apnea, trails injectable Zepbound

Eli Lilly's oral GLP-1 drug Foundayo met primary endpoints in two Phase 3 trials for obstructive sleep apnea, but efficacy appears lower than its injectable Zepbound. This expands the therapeutic scope of GLP-1s beyond diabetes and obesity, potentially broadening market access. Uncertainty remains on regulatory approval and comparative long-term outcomes.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works